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Article abstract
Mutations of the gene encoding the mitochondrial enzyme sterol 27-hydroxylase (CYP27A1 gene) cause defects in
the cholesterol pathway to bile acids that lead to the storage of cholestanol and cholesterol in tendons, lenses and
the central nervous system. This disorder is the cause of a clinical syndrome known as cerebrotendinous xantho-
matosis (CTX). Since 1991 several mutations of the CYP27A1 gene have been reported. We diagnosed the clinical
features of CTX in a caucasian woman. Serum levels of cholestanol and 7a-hydroxycholesterol were elevated and
the concentration of 27-hydroxycholesterol was reduced. Bile alcohols in the urine and faeces were increased. The
analysis of the CYP27A1 gene showed that the patient was a compound heterozygote carrying two mutations both
located in exon 8. One mutation is a novel four nucleotide deletion (c.1330-1333delTTCC) that results in a frame-
shift and the occurrence of a premature stop codon leading to the formation of a truncated protein of 448 amino
acids. The other mutation, previously reported, is a C - > T transition (c. c.1381C > T) that converts the glutamine
codon at position 461 into a termination codon (p.Q461X). These truncated proteins are expected to have no bio-
logical function being devoid of the cysteine residue at position 476 of the normal enzyme that is crucial for heme
binding and enzyme activity.
Introduction
Cerebrotendinous xanthomatosis (CTX) (OMIM
213700; ORPHA 909) [1,2] is an autosomal recessive
sterol storage disease caused by mutations of the sterol
27-hydroxylase-gene (CYP 27). The CYP27A1 gene is
located on chromosome 2q33-qter and consists of 9
exons. Sterol 27-hydroxylase is a mitochondrial cyto-
chrome P 450 enzyme that catalyzes the initial steps in
the oxidation of side chain of sterol intermediates in the
pathway leading to the formation of bile acids in the
liver [3-5]. In CTX patients the ability to convert choles-
terol to bile acids is impaired and the incomplete oxida-
tion of the cholesterol side chain leads to the
accumulation of cholesterol and abnormal tetra-and
penta-hydroxylated bile alcohols in tendons, lenses, the
central nervous system and lungs. Children with CTX
will often have diarrhea of unknown cause and develop
juvenile cataracts and tendon xanthomas [6]. Premature
atherosclerosis has also been observed. The characteris-
tic neurological features often leading to diagnosis in
the second or third decade of life are pyramidal tract
signs, cerebellar syndrome, peripheral neuropathy, epi-
leptic seizures, speech- and swallowing-disorders.
Currently, about 50 mutations of the CYP27A1 gene
are known [7-11], mainly affecting the adrenodoxin-
binding and heme binding-sites of the sterol 27-hydro-
xylase. Here we describe clinical findings, biochemical
parameters and a novel mutation of the CYP27A1 gene
in a woman with CTX.
Case presentation
The patient, a 35 year-old german female, complained of
a progressive disturbance of gait over the last 3 years.
She had a history of recurrent diarrhea and bronchitis,
growth retardation, a mild retardation of psychomotor
development in infancy and bilateral juvenile cataracts.
She attended a school for mentally and physically handi-
capped children. At age 24 a normal pregnancy and
delivered an apparently healthy child. Another child
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died four days after birth. There was no information
about the proband’s father so that consanguinity or clin-
ical features consistent with CTX in father’s family can-
not be excluded. The patient’s mother and daughter as
well as other known family members have no clinical
symptoms or signs of CTX.
Detailed physical examination revealed significant
findings of bilateral swelling of the Achilles tendons and
high arched feet. The patient had a tetraspastic syn-
drome with exaggerated tendon reflexes including the
masseter reflex, positive bilateral extensor plantar
responses and an unsteadiness of gait with difficulties in
walking in tandem. There was no Romberg sign. The
vibration sense was mildly impaired in the lower limbs.
Psychological testing revealed a slowing in psychomotor
activity with decrease of concentration and difficulties in
visual and abstract learning.
Routine laboratory tests were within normal limits.
Serum cholesterol was 143 mg/l and serum cholestanol
was 25.8 mg/l; cholestanol:cholesterol ratio was 1: 55
and increased to six times of normal limit; bile acid pre-
cursor 7a-hydroxycholesterol was 5068 ng/ml (normal
range 70-100 ng/ml) and 27-hydroxycholesterol 13 ng/
ml (normal range 70-100 ng/ml). Acid steroids and bile
alcohols in urine and faeces were also elevated. CSF
examination showed increased protein (611 mg/l) with
normal cell count, glucose and lactate levels.
The EEG revealed a posterior 4-5/s rhythm and addi-
tionally frontal intermittent rhythmic delta activity
(FIRDA). Somatosensory evoked potentials (tibialis
nerve) revealed borderline values for response at N22
(lumbar spinal cord) and a delayed response at P40 (cor-
tex) bilaterally of 50.6 ms and 51.1 ms indicating a cen-
tral demyelination. Nerve conduction studies showed
moderate reduction of motor conduction velocities
(tibial and peroneal nerve, 33-38 m/sec) suggesting mild
demyelination in the peripheral nervous system. Central
motor conduction times to tibialis anterior were pro-
longed (23.1 ms and 24.5 ms) indicating demyelination
of central motor pathways. MRI of head und cervical
spine was normal and MRI of Achilles tendons showed
confluent lipid inclusions.
Treatment with chenodeoxycholic acid was initiated
(750 mg/day). Three years later physical examination
revealed no progression of clinical manifestations.
Serum concentrations of cholesterol and cholestanol
were within normal limits. Nerve conduction studies
showed normal motor conduction velocities (tibial and
peroneal nerves) and central motor conduction times
were slightly prolonged to tibialis anterior (21,4 ms and
22,9 ms). EEG was improved with alpha rhythm and
without FIRDA. MRI of Achilles tendons showed
unchanged lipid inclusion.
Analysis of CYP27A1 Gene
Genomic DNA was extracted from peripheral blood leu-
kocytes by a standard procedure [12,13]. The promoter
region and the exons of CYP27 gene were amplified by
PCR from genomic DNA using the primers reported
previously by Leitersdorf et al. [7]. PCR products were
sequenced directly (Thermosequenase kit, USB Amer-
sham, UK.). For the sequence of the exon 6 - exon 9
region we used the following oligonucleotides: 5′ GAG
ATC CAG GAG GCC TTG CAC GA 3′ (forward pri-
mer in exon 6 corresponding to nucleotides 1066-1089
of the cDNA) (6S); 5′ GAT TGG GCA GCA TGA ATG
CCA CTC 3′ (reverse primer complementary to nucleo-
tides 75-52 of intron 7) (7B); 5′ CCC AGT TTG TGT
TCT GCC AC 3′ (forward primer in exon 8 correspond-
ing to nucleotides 1265 - 1285 of the cDNA) (8S); 5′
GGA GTA GCT GCA TCT CCA GCT CT 3′ (reverse
primer in exon 8 complementary to nucleotides 1468 -
1447 of the cDNA) (8AS); 5′ CCC AGC AAG GCG
GAG ACT CA 3′ (reverse primer in the 3′ untranslated
region complementary to nucleotides 1618 - 1600 of the
cDNA) (9B).
To confirm the presence of the mutations in exon 8 of
CYP27A1 gene found by sequencing (see below) the
exon 6 - exon 9 region was amplified by PCR and the
fragment digested with the restriction enzymes Hind III
or BamHI. The restriction fragments were separated by
1% agarose gel electrophoresis.
Mutations in CYP27A1 Gene
Figures 1 and 2 show that the patient was a compound
heterozygote carrying two mutations in exon 8: i) a 4
nucleotide deletion (TTCC) (c.1330-1333 del TTCC)
and ii) a C- > T transition (c.1381C > T). The four
nucleotide deletion causes a shift in the reading frame
downstream of the codon for serine (p.S443) leading to
a sequence of five novel amino acids preceding a prema-
ture stop codon (p.S443 > Fs > X449). The presence of
the four nucleotide deletion was confirmed by restric-
tion fragment analysis, as this deletion eliminates a Hin-
dIII restriction site. The digestion of exon 6 - exon 9
region generated two fragments of 631 bp and 445 bp
respectively in control DNA and a single fragment of
1076 bp in patient’s DNA.
The second mutation is a non-sense mutation which
converts the codon (CAG) for glutamine (p.Q461) into a
stop codon. This mutation was previously reported as
Q428X in the mature protein [10] or Q461X in the pre-
protein (that includes the 33 amino acid of the mito-
chondrial signal peptide) [11]. The presence of the
mutation was confirmed by restriction fragment analysis,
due to the elimination of BamHI restriction site. The
digestion of exon 6 - exon 9 region generated two
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Figure 1 Partial nucleotide sequence of exon 8 in proband D.R. and in a control subject (C.). Patient is heterozygous for a 4 nucleotides
deletion (boxed) (c.1330-1333delTTCC). This deletion causes a shift in the reading frame resulting in a string of five novel amino acids (in italics)
and the occurrence of a premature stop codon.
Figure 2 Partial nucleotide sequence of exon 8 in patient and in a control subject (C.). Patient is heterozygous for C- > T transition at CYP
cDNA position c.1381 (p.Q461X).
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fragments of 681 bp and 395 bp respectively in control
DNA and a single fragment of 1076 in patient’s DNA.
Patient’s daughter was heterozygote for the 4 nucleo-
tide deletion (data not shown).
Conclusion
Two decades after the first report describing defects in
sterol 27-hydroxylase as underlying cause of the autoso-
mal recessive disease cerebrotendinous xanthomatosis
(CTX), several mutations in the CYP27A1 gene have
been described [11].
The sequence analysis of CYP27A1 gene in our CTX
patient revealed two mutations, leading to the formation
of truncated proteins. The first mutation is a deletion of
four nucleotides in exon 8 (c.1330-1333del TTCC) gen-
erating a frameshift with a premature termination codon
and resulting in a truncated protein of 448 amino acids.
To our knowledge this is the first 4 nt deletion reported
in CYP27 gene in a CTX patient. In other genetic dis-
eases this deletion occurs in a context of DNA sequence
characterized by several direct or inverted short nucleo-
tide repeats [14]. The presence of these repeats is
thought to be cause for slipped mispairing at the DNA
replication [15] that, in turn, may produce minute dele-
tions or insertions.
The second mutation is a C - > T transition at cDNA
position c.1381 (exon 8) that converts codon CAG (p.
Q461X) into TAG (stop) leading to a truncated protein
of 460 amino acids.
The truncated proteins encoded by the mutant alleles
found in our patient are devoid of the cysteine at posi-
tion p.476 of the normal enzyme, which has been shown
to be crucial for heme binding and enzyme activity [16].
Therefore, although we have not done in vitro expres-
sion studies with mutant cDNAs, it is most likely that
lack of a functional heme binding domain in the trun-
cated proteins results in a decreased activity of the sterol
27-hydroxylase and the CTX phenotype of our patient.
DNA analysis of the patient’s daughter revealed that
she is heterozygous for the 4 nucleotide deletion.
Although she is expected to have a 50% reduction of
sterol 27-hydroxylase activity in liver and other tissues,
she is free of symptoms as it is usually the case in car-
riers of a single mutation of CYP27A1 gene. It is sup-
posed that only a reduction of enzyme activity greater
than 90% results in an increased production of metabo-
lites like cholestanol or bile alcohols, partially responsi-
ble for the clinical phenotype in CTX subjects [17].
We know that both of the patient’s parents are of the
same caucasian background and her mother is free of
clinical signs associated with CTX. Further diagnostic
studies and genetic analyses of the patient’s family were
declined and therefore it remains unclear whether our
patient received these mutations from her parents or
carries “de novo” mutations.
Several compound heterozygous patients have been
described [7,18-23]. As pointed out in a retrospective
study evaluation of these patients and the comparison
with individuals homozygous for CTX mutations
revealed no clear genotype-phenotype relations [8]. This
is consistent with earlier findings suggesting a strong
influence of environmental and other genetic factors on
the development of individual CTX phenotypes [21].
Knockout mice deficient in the sterol 27-hydroxylase
(cyp27-/-) have been generated by gene targeting [24].
The disruption of the sterol 27-hydroxylase gene in mice
did not lead to neurological, metabolic or vascular altera-
tions similar to those observed in CTX patients most
likely due to species differences in the bile acid and cho-
lesterol metabolism. The CYP27 -/- mice therefore are
not a suitable model for investigating the pathophysiol-
ogy of sterol accumulation in tissues in CTX patients.
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